Market Overview:
The global HER-2 targeted drugs for breast cancer market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of breast cancer, technological advancements in the field of oncology, and rising awareness about HER-2 targeted drugs. The global HER-2 targeted drugs for breast cancer market is segmented by type into trastuzumab, pertuzumab, lapatinib, neratinib, trastuzumab emtansine (TACE), pyrotinib and other types. Trastuzumab held the largest share of the global HER-2 targeted drugs for breast cancer market in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy and safety profile compared with other types of HER-2 targeting drugs. Lapatinib is another major type of drug which is used for treating patients with advanced stages of breast cancer. It held a significant share in 2017 owing to its high efficacy in treating patients with metastatic disease who are resistant or intolerant to trastuzumab therapy.
Product Definition:
HER-2 Targeted Drugs for Breast Cancer are a type of drug that is specifically designed to target and kill cells that have the HER-2 protein on their surface. These drugs are important because they can be very effective in treating breast cancer that is HER-2 positive.
Trastuzumab:
Trastuzumab, also known as Herceptin, is a humanized monoclonal antibody that targets the HER-2/neu oncogene. This drug has been approved by the U.S. FDA for breast cancer treatment and is marketed under various brand names such as Herceptin (Genentech), Reblozumab (Rolontis), and Avastin (Alvinomycin).
Pertuzumab:
Pertuzumab (ERT2) is a HER-2 targeted drug that works by blocking the activity of the HER-2 oncogene. The product was approved by the FDA in 2013 for treatment of early breast cancer and in 2014 for patients with metastatic breast cancer who are candidates for trastuzumab emtansine.
Application Insights:
The hospital application segment dominated the global market for HER-2 targeted drugs for breast cancer with a revenue share of over 60% in 2017. The high preference towards institutional treatment is one of the major factors contributing to this large share. Moreover, increasing awareness about advanced treatments and growing availability of healthcare facilities are also responsible for driving this segment.
In most cases, trastuzumab is preferred over other drugs as it has fewer side effects and costs less than pertuzumab or lapatinib. However, these three medicines together offer effective treatment in most cases; hence they are being prescribed together by doctors mostly through national Breast Cancer Networks (CAN) or via collaborations with hospitals and clinics around the world (such as those facilitated by ICON).
Regional Analysis:
North America dominated the global market in 2017, with a revenue share of over 40.0%. This is attributed to the high incidence rate of HER-2 positive breast cancer and increasing awareness about early diagnosis. Moreover, rising healthcare expenditure and reimbursement coverage are also expected to drive growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to an increase in per capita income, which enables people from low-income households access advanced treatment options for oncological diseases at affordable prices. In addition, growing awareness about early detection among women population will further boost regional growth during the forecast period.
Growth Factors:
- Increasing incidence of breast cancer
- Growing awareness about HER-2 targeted drugs for breast cancer treatment
- Rising demand for better and advanced therapies for breast cancer treatment
- Technological advancements in the field of oncology
- Availability of government funding and initiatives to support research and development in the field of oncology
Scope Of The Report
Report Attributes
Report Details
Report Title
HER-2 Targeted Drugs for Breast Cancer Market Research Report
By Type
Trastuzumab, Pertuzumab, Lapatinib, Neratinib, Trastuzumab Emtansine, Pyrotinib, Other
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Roche, Chugai Pharmaceutical, GlaxoSmithKline, Novartis, Pfizer, CANbridge, Puma Biotechnology, Hengrui Medicine, Beacon Pharmaceuticals Limited, Hetero Drugs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global HER-2 Targeted Drugs for Breast Cancer Market Report Segments:
The global HER-2 Targeted Drugs for Breast Cancer market is segmented on the basis of:
Types
Trastuzumab, Pertuzumab, Lapatinib, Neratinib, Trastuzumab Emtansine, Pyrotinib, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Chugai Pharmaceutical
- GlaxoSmithKline
- Novartis
- Pfizer
- CANbridge
- Puma Biotechnology
- Hengrui Medicine
- Beacon Pharmaceuticals Limited
- Hetero Drugs
Highlights of The HER-2 Targeted Drugs for Breast Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Trastuzumab
- Pertuzumab
- Lapatinib
- Neratinib
- Trastuzumab Emtansine
- Pyrotinib
- Other
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the HER-2 Targeted Drugs for Breast Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
HER-2 targeted drugs are medications that block the growth of cancer cells that overexpress HER-2. These drugs can be used to treat various types of breast cancer.
Some of the major players in the her-2 targeted drugs for breast cancer market are Roche, Chugai Pharmaceutical, GlaxoSmithKline, Novartis, Pfizer, CANbridge, Puma Biotechnology, Hengrui Medicine, Beacon Pharmaceuticals Limited, Hetero Drugs.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 HER-2 Targeted Drugs for Breast Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 HER-2 Targeted Drugs for Breast Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 HER-2 Targeted Drugs for Breast Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the HER-2 Targeted Drugs for Breast Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global HER-2 Targeted Drugs for Breast Cancer Market Size & Forecast, 2018-2028
4.5.1 HER-2 Targeted Drugs for Breast Cancer Market Size and Y-o-Y Growth
4.5.2 HER-2 Targeted Drugs for Breast Cancer Market Absolute $ Opportunity
Chapter 5 Global HER-2 Targeted Drugs for Breast Cancer Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Type
5.2.1 Trastuzumab
5.2.2 Pertuzumab
5.2.3 Lapatinib
5.2.4 Neratinib
5.2.5 Trastuzumab Emtansine
5.2.6 Pyrotinib
5.2.7 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global HER-2 Targeted Drugs for Breast Cancer Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global HER-2 Targeted Drugs for Breast Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America HER-2 Targeted Drugs for Breast Cancer Analysis and Forecast
9.1 Introduction
9.2 North America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Type
9.6.1 Trastuzumab
9.6.2 Pertuzumab
9.6.3 Lapatinib
9.6.4 Neratinib
9.6.5 Trastuzumab Emtansine
9.6.6 Pyrotinib
9.6.7 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe HER-2 Targeted Drugs for Breast Cancer Analysis and Forecast
10.1 Introduction
10.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Type
10.6.1 Trastuzumab
10.6.2 Pertuzumab
10.6.3 Lapatinib
10.6.4 Neratinib
10.6.5 Trastuzumab Emtansine
10.6.6 Pyrotinib
10.6.7 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific HER-2 Targeted Drugs for Breast Cancer Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Type
11.6.1 Trastuzumab
11.6.2 Pertuzumab
11.6.3 Lapatinib
11.6.4 Neratinib
11.6.5 Trastuzumab Emtansine
11.6.6 Pyrotinib
11.6.7 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America HER-2 Targeted Drugs for Breast Cancer Analysis and Forecast
12.1 Introduction
12.2 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Type
12.6.1 Trastuzumab
12.6.2 Pertuzumab
12.6.3 Lapatinib
12.6.4 Neratinib
12.6.5 Trastuzumab Emtansine
12.6.6 Pyrotinib
12.6.7 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) HER-2 Targeted Drugs for Breast Cancer Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Type
13.6.1 Trastuzumab
13.6.2 Pertuzumab
13.6.3 Lapatinib
13.6.4 Neratinib
13.6.5 Trastuzumab Emtansine
13.6.6 Pyrotinib
13.6.7 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 HER-2 Targeted Drugs for Breast Cancer Market: Competitive Dashboard
14.2 Global HER-2 Targeted Drugs for Breast Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Chugai Pharmaceutical
14.3.3 GlaxoSmithKline
14.3.4 Novartis
14.3.5 Pfizer
14.3.6 CANbridge
14.3.7 Puma Biotechnology
14.3.8 Hengrui Medicine
14.3.9 Beacon Pharmaceuticals Limited
14.3.10 Hetero Drugs
